

Tumor Board Tuesday – June 14, 2022
Adjuvant Treatment in EGFR Mutated Lung Cancer Posttest Rationale

1. **What biomarker testing would you request before selecting adjuvant treatment for a patient with stage IIB NSCLC who underwent resection?**
 - a. ALK
 - b. BRAF
 - c. EGFR
 - d. ROS1

Rationale: Testing for *EGFR* mutations should be performed when adjuvant TKI therapy is a consideration for patients with stage IB to IIIA NSCLC. EGFR targeted therapy with osimertinib is a recommended adjuvant treatment for patients with completely resected stage IB to IIIA, *EGFR*-mutant (*exon 19 deletion, L858R*) NSCLC who received previous adjuvant chemotherapy or are ineligible for platinum-based chemotherapy.

References:

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Non-Small Cell Lung Cancer (v3.2022). Updated March 16, 2022. Accessed April 13, 2022. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

2. **What adjuvant treatment would you select for a patient with diabetes, presbycusis, and peripheral neuropathy-based therapy with resected (R0) EGFR L858R NSCLC?**
 - a. Chemotherapy
 - b. Chemo & Osimertinib
 - c. Osimertinib

Rationale: Osimertinib is FDA-indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. The NCCN guidelines recommend adjuvant osimertinib recommended for patients with completely resected stage IB to IIIA, *EGFR*-mutant (*exon 19 deletion, L858R*) NSCLC who received previous adjuvant chemotherapy or are ineligible for platinum-based chemotherapy.

References:

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Non-Small Cell Lung Cancer (v3.2022). Updated March 16, 2022. Accessed April 13, 2022. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

TAGRISSO® (osimertinib) [prescribing information]. AstraZeneca. Approved 2015. Revised January 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208065s0251bl.pdf